Multi-institutional study on the definition of new predictive biomarkers of response in resectable pancreatic adenocarcinoma, with poor prognostic factors, treated with neoadjuvants. Serum pharmacoproteomic correlation of response to treatment. Development of a prognostic/predictive biosensor from this experience.